^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Soft Tissue Sarcoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    03/29/2022
    Excerpt:
    Soft Tissue Sarcoma...Preferred regimens...Pembrolizumab in combination with axitinib